Celldex Therapeutics (CLDX) Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Celldex Therapeutics in the last year. There are currently 1 sell rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CLDX shares.
View CLDX analyst ratings or view top-rated stocks.

4 Wall Street research analysts have issued 1 year price targets for Celldex Therapeutics' shares. Their CLDX share price forecasts range from $54.00 to $73.00. On average, they expect the company's stock price to reach $63.33 in the next twelve months. This suggests a possible upside of 141.4% from the stock's current price.
View analysts price targets for CLDX or view top-rated stocks among Wall Street analysts.

Celldex Therapeutics' stock was trading at $44.57 at the beginning of 2023. Since then, CLDX shares have decreased by 41.1% and is now trading at $26.24.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our CLDX earnings forecast.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced its earnings results on Tuesday, August, 8th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.65). The biopharmaceutical company had revenue of $0.27 million for the quarter, compared to the consensus estimate of $0.67 million. Celldex Therapeutics had a negative net margin of 3,475.70% and a negative trailing twelve-month return on equity of 36.15%.

ETFs with the largest weight of Celldex Therapeutics (NASDAQ:CLDX) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO).SPDR S&P Biotech ETF (XBI).

Celldex Therapeutics's stock reverse split on Monday, February 11th 2019. The 1-15 reverse split was announced on Friday, February 8th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 8th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Celldex Therapeutics investors own include OPKO Health (OPK), Gilead Sciences (GILD), ACADIA Pharmaceuticals (ACAD), Corbus Pharmaceuticals (CRBP), Precigen (PGEN), Micron Technology (MU), Dynavax Technologies (DVAX), Exelixis (EXEL), bluebird bio (BLUE) and SCYNEXIS (SCYX).

Celldex Therapeutics trades on the NASDAQ under the ticker symbol "CLDX."

Celldex Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.82%), State Street Corp (5.77%), Kynam Capital Management LP (5.50%), Polar Capital Holdings Plc (5.11%), Jennison Associates LLC (2.81%) and Point72 Asset Management L.P. (2.51%). Insiders that own company stock include Diane C Young, Elizabeth Crowley, Freddy A Jimenez, Richard M Wright, Samuel Bates Martin and Sarah Cavanaugh.
View institutional ownership trends.

Shares of CLDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CLDX stock can currently be purchased for approximately $26.24.

Celldex Therapeutics (NASDAQ:CLDX) has a market capitalization of $1.24 billion and generates $2.36 million in revenue each year. The biopharmaceutical company earns $-112,320,000.00 in net income (profit) each year or ($2.40) on an earnings per share basis.

The company employs 148 workers across the globe.

Celldex Therapeutics' mailing address is 53 FRONTAGE ROAD SUITE 220, HAMPTON NJ, 08827. The official website for the company is www.celldex.com. The biopharmaceutical company can be reached via phone at (908) 454-7120, via email at ir@celldextherapeutics.com, or via fax at 908-454-1911.